Skip to main content

Table 1 Meta-analysis of Danhong injection with the changes in plasma lipid levels

From: The lipid-lowering effects of Danhong and Huangqi injections: a meta-analysis of clinical controlled trials

Groups or subgroups Studies (Subjects) P Heterogeneity SMD (95% CI) P SMD
Triglycerides
 All 38 (4213) <  0.001 − 0.76 (− 0.91, − 0.61) <  0.001
 Coronary artery disease 7 (790) <  0.001 − 0.52 (− 0.88, − 0.16) <  0.01
 Cerebrovascular disease 16 (2218) <  0.001 − 0.94 (− 1.13, − 0.74) <  0.001
 Diabetes 9 (695) 0.001 − 0.58 (− 0.87, − 0.29) <  0.001
 Hyperlipidemia 5 (444) <  0.001 − 0.87 (− 1.54, − 0.20) <  0.05
 Low-dose (≤ 20 mL) 13 (1257) <  0.001 − 0.90 (− 1.15, − 0.66) <  0.001
 High-dose (>  20 mL) 25 (2956) <  0.001 − 0.69 (− 0.88, − 0.50) <  0.001
 Short-duration (≤ 2 weeks) 20 (2472) <  0.001 − 0.76 (− 0.99, − 0.53) <  0.001
 Long-duration (>  2 weeks) 17 (1661) <  0.001 − 0.80 (− 0.99, − 0.61) <  0.001
Total cholesterol
 All 41 (4781) <  0.001 − 1.29 (− 1.56, − 1.03) <  0.001
 Coronary artery disease 7 (982) <  0.001 − 1.12 (− 1.85, − 0.40) <  0.01
 Cerebrovascular disease 18 (2390) <  0.001 − 1.53 (− 1.94, − 1.13) <  0.001
 Diabetes 9 (695) <  0.001 − 1.28 (− 1.87, − 0.70) <  0.001
 Hyperlipidemia 6 (648) 0.08 −1.16 (− 1.46, − 0.86) <  0.001
 Low-dose (≤ 20 mL) 13 (1449) <  0.001 − 1.13 (− 1.49, − 0.78) <  0.001
 High-dose (>  20 mL) 28 (3332) <  0.001 − 1.38 (− 1.73, − 1.02) <  0.001
 Short-duration (≤ 2 weeks) 21 (2544) <  0.001 − 1.12 (− 1.38, − 0.86) <  0.001
 Long-duration (>  2 weeks) 19 (2157) <  0.001 − 1.42 (− 1.92, − 0.92) <  0.001
LDL-C     
 All 38 (4412) <  0.001 − 0.76 (− 0.93, − 0.59) <  0.001
 Coronary artery disease 8 (1012) <  0.001 − 0.72 (− 1.15, − 0.30) 0.001
 Cerebrovascular disease 16 (2183) <  0.001 − 0.94 (− 1.24, − 0.64) <  0.001
 Diabetes 7 (503) 0.02 − 0.56 (− 0.86, − 0.26) <  0.001
 Hyperlipidemia 5 (444) 0.34 −0.54 (− 0.74, − 0.34) <  0.001
 Low-dose (≤ 20 mL) 14 (1579) <  0.001 − 0.79 (− 1.05, − 0.53) <  0.001
 High-dose (>  20 mL) 24 (2833) <  0.001 − 0.74 (− 0.96, − 0.52) <  0.001
 Short-duration (≤ 2 weeks) 18 (2115) <  0.001 − 0.71 (− 0.92, − 0.50) <  0.001
 Long-duration (>  2 weeks) 19 (2217) <  0.001 −0.85 (− 1.11, − 0.58) <  0.001
HDL-C
 All 32 (3616) <  0.001 0.70 (0.41, 0.98) <  0.001
 Coronary artery disease 5 (500) <  0.001 0.75 (−0.00, 1.50) 0.05
 Cerebrovascular disease 17 (2318) <  0.001 0.98 (0.55, 1.41) <  0.001
 Diabetes 4 (288) 0.10 0.32 (−0.07, 0.70) 0.10
 Hyperlipidemia 5 (444) <  0.001 0.19 (−0.32, 0.69) 0.47
 Low-dose (≤ 20 mL) 11 (1032) <  0.01 0.53 (0.33, 0.73) <  0.001
 High-dose (>  20 mL) 21 (2584) <  0.001 0.79 (0.38, 1.21) <  0.001
 Short-duration (≤ 2 weeks) 16 (2070) <  0.001 0.92 (0.55, 1.29) <  0.001
 Long-duration (>  2 weeks) 15 (1466) <  0.001 0.51 (0.07, 0.95) 0.02
  1. SMD standardized mean difference, 95% CI 95% confidence interval, TG triglycerides, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol